Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 25 IN PLASTIC CONTAINER.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Travasol 2.75% in Dextrose 25% is a parenteral nutrition solution providing amino acids and carbohydrates. The amino acids serve as substrates for protein synthesis, while dextrose provides a source of calories and spares protein catabolism. It does not have a direct pharmacological target but supports metabolic functions.
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous administration only. Typical adult dose is 1 to 2 L per day, infused at a rate of 100 to 200 mL per hour, adjusted based on metabolic and fluid needs. Contains 2.75% amino acids and 25% dextrose.
None Documented
None Documented
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Not applicable as a single entity; amino acids have variable half-lives (minutes to hours), dextrose has a half-life of 1.5-2 hours in normoglycemic patients; clinical context: continuous infusion maintains steady state.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal: 100% as amino acids and dextrose metabolites; negligible biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution